Redbiotec closes deal with Roche. Redbiotec AG, the leader in protein complexes and designer virus-like particles (VLP) enters into a collaboration with Roche, by which it will apply its proprietary technology platform [rePAX®] to an undisclosed discovery area. After having successfully worked for two leading global vaccine players in 2010, the deal with Roche is an additional highlight of a successful year for Redbiotec.